| [1] |
Morin DP, Bernard ML, Madias C, et al. The state of the art: atrial fibrillation epidemiology, prevention, and treatment[J]. Mayo Clin Proc, 2016, 91(12):1778-1810.
|
| [2] |
Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective[J]. Clin Epidemiol, 2014, 6:213-220.
|
| [3] |
Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007[J]. Circ Cardiovasc Qual Outcomes, 2012, 5(1):85-93.
|
| [4] |
Guo Y, Tian Y, Wang H, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation[J]. Chest, 2015, 147(1):109-119.
|
| [5] |
Saposnik G, Gladstone D, Raptis R, et al. Atrial fibrillation in ischemic stroke: predicting response to thrombolysis and clinical outcomes[J]. Stroke, 2013, 44(1):99-104.
|
| [6] |
McGrath ER, Kapral MK, Fang J, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke[J]. Neurology, 2013, 81(9):825-832.
|
| [7] |
Mohan KM, Crichton SL, Grieve AP, et al. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register[J]. J Neurol Neurosurg Psychiatry, 2009, 80(9):1012-1018.
|
| [8] |
Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study[J]. Stroke, 1996, 27(10):1760-1764.
|
| [9] |
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study[J]. Stroke, 1991, 22(8):983-988.
|
| [10] |
Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review[J]. Neurology, 2007, 69(6):546-554.
|
| [11] |
Li LH, Sheng CS, Hu BC, et al. The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study[J]. BMC Cardiovasc Disord, 2015, 15:31.
|
| [12] |
Soo Y, Chan N, Leung KT, et al. Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack, anticoagulant use and risk factor profile in Chinese population: a 15-year study[J]. J Neurol Neurosurg Psychiatry, 2017, 88(9):744-748.
|
| [13] |
Fumagalli S, Said SAM, Laroche C, et al. Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: the EUR Observational Research Programme – Atrial Fibrillation (EORP-AF) General Pilot Registry (EUR Observational Research Programme-Atrial Fibrillation)[J]. JACC Clin Electrophysiol, 2015, 1(4):326-334.
|
| [14] |
Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation[J]. Circulation, 2007, 115(21):2689-2696.
|
| [15] |
Graham D J, Reichman M E, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation[J]. Circulation, 2015, 131(2):157-164.
|
| [16] |
Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)[J]. Circulation, 2014, 130(2):138-146.
|
| [17] |
Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial[J]. Eur Heart J, 2014, 35(28):1864-1872.
|
| [18] |
Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J]. J Arrhythm, 2017, 33(4):345-367.
|
| [19] |
Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis[J]. Eur Heart J, 2015, 36(46):3238-3249.
|
| [20] |
Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study[J]. Circulation, 2012, 125(19):2298-2307.
|
| [21] |
Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients[J]. Am Heart J, 2011, 161(2):241-246.
|
| [22] |
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007, 146(12):857-867.
|
| [23] |
Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial[J]. Lancet, 2007, 370(9586):493-503.
|
| [24] |
Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2014, 7(2):300-306.
|
| [25] |
Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort[J]. Europace, 2016, 18(9):1308-1318.
|
| [26] |
Chang SS, Dong JZ, Ma CS, et al. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study[J]. Stroke, 2016, 47(7):1803-1810.
|
| [27] |
Guo Y, Wang H, Tian Y, et al. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation[J]. Chest, 2015, 148(1):62-72.
|
| [28] |
Wang ZZ, Du X, Wang W, et al. Long-Term Persistence of Newly Initiated Warfarin Therapy in Chinese Patients With Nonvalvular Atrial Fibrillation[J]. Circ Cardiovasc Qual Outcomes, 2016, 9(4):380-387.
|
| [29] |
Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry[J]. Circulation, 2014, 129(15):1568-1576.
|
| [30] |
Li WH, Huang D, Chiang CE, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project[J]. Clin Cardiol, 2017, 40(4):222-229.
|
| [31] |
Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists[J]. Europace, 2015, 17(5):711-717.
|
| [32] |
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921):955-962.
|
| [33] |
Lip GY, Wang KL, Chi ang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal[J]. Int J Cardiol, 2015, 180:246-254.
|
| [34] |
《老年人心房颤动诊治中国专家建议》写作组，中华医学会老年医学分会，中华老年医学杂志编辑委员会.老年人非瓣膜性心房颤动诊治中国专家建议(2016)[J]. 中华老年医学杂志, 2016, 35(9):915-928.
|
| [35] |
Freedman JE, Gersh BJ. Atrial fibrillation and stroke prevention in aging patients: what's good can be even better[J]. Circulation, 2014, 130(2):129-131.
|